MCL1 and skin basal cell carcinoma: In both BCC and AGS control cells, IMQ treatment led to a decrease in the expression of TOM20, as illustrated in Figure 5B. Surprisingly, we found that TOM20 was overexpressed in 12A and AGS IV cells and that the expression of TOM20 was even increased in both types of IMQ-treated Mcl-1-overexpressing cells.